PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer

BACKGROUND: Even though trastuzumab is an effective therapy in early stage Her-2+ breast cancer, 40–50% of advanced Her-2+ breast cancer patients develop trastuzumab resistance. A potential resistance mechanism is aberrant downstream signal transmission due to loss of phosphatase and tensin homologu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gschwantler-Kaulich, Daphne, Tan, Yen Y., Fuchs, Eva-Maria, Hudelist, Gernot, Köstler, Wolfgang J., Reiner, Angelika, Leser, Carmen, Salama, Mohamed, Attems, Johannes, Deutschmann, Christine, Zielinski, Christoph C., Singer, Christian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333838/
https://www.ncbi.nlm.nih.gov/pubmed/28253285
http://dx.doi.org/10.1371/journal.pone.0172911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333838/
https://www.ncbi.nlm.nih.gov/pubmed/28253285
http://dx.doi.org/10.1371/journal.pone.0172911

Ejemplares similares